1
Home
Companies

Generation Bio

#9871

Rank

$35.98M

Marketcap

US United States

Country

Generation Bio
Leadership team

Dr. Cameron Geoffrey McDonough M.D. (Pres, CEO, Sec. & Director)

Dr. Matthew Norkunas M.B.A., M.D. (Chief Financial Officer)

Dr. Matthew Stanton Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology, Genetics, Health Care
Number of Employees
100 - 500
Headquarters
Cambridge, Massachusetts, United States
Established
2016
Company Registration
SEC CIK number: 0001733294
Traded as
GBIO
Social Media
URL
https://generationbio.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
History

Generation Bio was founded in 2017 by MIT alumnus Noubar Afeyan and members of his Cambridge-based venture capital firm Flagship Pioneering. The company received its first funding from a syndicate of investors, including Novartis, which provided an initial $90M Series A financing. In 2019, Generation Bio closed a $200M Series B financing round led by affiliate investors of SoftBank’s Vision Fund.

Mission
Generation Bio is focused on translating its proprietary SRS-A technology into innovative medicines that address unmet needs in rare genetic diseases and hearing loss. The company's goal is to develop a platform for gene therapies that will treat the underlying cause of disease with a single dose.
Vision
Generation Bio's vision is to develop transformative therapies that address the underlying cause of rare genetic diseases and deafness with a single-dose that can be administered to a range of patients.
Key Team

Dr. Douglas Kerr M.B.A., M.D., Ph.D. (Chief Medical Officer)

Dr. Tracy Zimmermann Ph.D. (Chief Devel. Officer)

Dr. Mark D. Angelino Ph.D. (Co-Founder)

Dr. Robert Kotin Ph.D. (Co-Founder & Advisor)

Ms. Antionette Paone M.B.A., M.S. (Chief Operating Officer)

Dr. Jennifer Elliott Esq., J.D., Ph.D. (Chief Legal Officer)

Dr. Phillip Samayoa Ph.D. (Chief Strategy Officer)

Recognition and Awards
Generation Bio’s SRS-A technology platform has been recognized as a new frontier in gene therapy treatment by numerous organizations, including being named one of the 50 technologies shaping the future of healthcare by Fast Company and a “Top 10 Tech Breakthrough of the Year” by the MIT Technology Review.
References

https://in.investing.com/equities/generation-bio-co

https://finance.yahoo.com/quote/GBIO/profile?p=GBIO

https://www.crunchbase.com/organization/generation-bio

https://companiesmarketcap.com/

https://generationbio.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Generation Bio
Leadership team

Dr. Cameron Geoffrey McDonough M.D. (Pres, CEO, Sec. & Director)

Dr. Matthew Norkunas M.B.A., M.D. (Chief Financial Officer)

Dr. Matthew Stanton Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology, Genetics, Health Care
Number of Employees
100 - 500
Headquarters
Cambridge, Massachusetts, United States
Established
2016
Company Registration
SEC CIK number: 0001733294
Traded as
GBIO
Social Media
URL
https://generationbio.com